Anacor Completes Enrollment in Second of Two Phase 3 Trials of Tavaborole

Anacor Pharmaceuticals has completed the enrollment of approximately 600 patients in the second of its two Phase 3 trials of tavaborole.

Anacor Pharmaceuticals has completed the enrollment of approximately 600 patients in the second of its two Phase 3 trials of tavaborole (formerly known as AN2690), a topical anti-fungal product candidate for the treatment of onychomycosis.

The tavaborole Phase 3 program consists of two double-blind, vehicle-controlled trials with two-to-one randomization between tavaborole and vehicle (the topical formulation without the active ingredient).

The tavaborole Phase 3 treatment regimen involves once-daily dosing for 48 weeks. The primary efficacy endpoint is a complete cure of the great toenail at week 52 as agreed upon under a Special Protocol Assessment with the FDA. Complete cure is a composite endpoint which requires both a mycologic cure and a completely clear na